AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 183 min read$ABT

Why Wall Street Is Becoming Even More Bullish About This Dividend King

Abbott Laboratories (NYSE: ABT) reported Q2 2026 sales of $12.6B, up 13%, and raised its full-year adjusted EPS forecast to $5.45-$5.60. Analysts are bullish, citing growth in its Medical Devices segment and recent acquisitions. The stock has 21 'buy' ratings with target prices up to $143. Abbott's dividend history and growth prospects are key attractions for investors.

Original reporting
theglobeandmail.com
Published Sep 18, 2026, 9:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Why Wall Street Is Becoming Even More Bullish About This Dividend King — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ABTBullishHigh
01

Why it matters

The earnings beat and guidance raise reinforce Abbott's growth narrative, likely supporting its dividend appeal and attracting income‑focused investors.

02

Market read

Abbott's stronger-than-expected earnings and raised guidance provide a fresh catalyst for the stock and may influence broader healthcare sector sentiment.

03

What to watch

Potential near‑term earnings drag from the Exact Sciences acquisition and mixed performance in other segments.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Abbott Laboratories, a long‑standing Dividend King, posted Q2 2026 results with strong device growth and raised full‑year EPS outlook.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott reported Q2 2026 sales of $12.6 B, EPS $1.31 and raised FY adjusted EPS guidance to $5.45‑$5.60.

Expected impact

potential upside of 5‑10% over the next weeks

Evidence & confidence

Guidance lift and robust device segment growth exceed expectations for a Dividend King, reducing downside risk.

Market effects

Sector

Medical devices and diabetes monitoring segments may see increased investor interest, lifting peers in healthcare equipment.

Regional

U.S. healthcare sector gains as a leading Dividend King shows stronger growth.

Global

Positive earnings from a large cap health company can boost global health‑care indices.

Counterpoint

What could challenge this read

Higher valuation (33× earnings) leaves little margin for error; slower growth in nutrition and diagnostics could pressure the stock.

Key entities

  • company
    Abbott Laboratories

    U.S. healthcare company and Dividend King.

  • company
    Exact Sciences

    Acquired cancer‑screening firm now part of Abbott.

Read at source← All news

Related articles

SEP 19
$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

wpdh.com2 min
SEP 18
$ABTLowAI 8/10

Abbott to pay $385 million over Michigan baby formula recall that fueled 2022 shortage

Abbott Laboratories agreed to a $385 million settlement over its 2022 recall of baby formula from its Michigan plant, which exacerbated a nationwide shortage. The settlement resolves claims from the DOJ, relators, and state attorneys general. Abbott denies fault or liability. The plant was closed due to contamination concerns but reopened by June 2022. The Biden administration took emergency measures to address the shortage.

finance.yahoo.com2 min
SEP 17
$ABTMedAI 8/10

Attorney General James Secures Over $9 Million for New York from Abbott Laboratories for Manufacturing Potentially Unsafe Baby Formula

New York Attorney General Letitia James announced a settlement with Abbott Laboratories, where the company will pay over $384 million for alleged safety violations in its baby formula products. Abbott is accused of failing to maintain safety standards from 2018 to 2022, leading to potential contamination and misuse of Medicaid and WIC funds. New York will receive over $9.3 million from the settlement.

longisland.com2 min
SEP 17
$ABTMedAI 8/10

Abbott Must Pay $384M for 2022 Contaminated Baby Formula: Who Gets the Payout

Abbott Laboratories agreed to pay $385M to settle allegations of selling contaminated infant formula to government programs, contributing to the 2022 formula crisis. The settlement resolves False Claims Act allegations but does not establish a consumer claims process. The Justice Department emphasized the importance of adhering to health and safety standards for infant formula.

newsweek.com6 min